Ledipasvir/sofosbuvir (Harvoni®)

Assessment Status Assessment process complete
Drug Ledipasvir/sofosbuvir
Brand Harvoni®
Indication For the treatment of Chronic Hepatitis C (CHC) infection (Genotye 1, 3 and 4)  in adults.
Assessment Process
Rapid review commissioned 14/11/2014
Rapid review completed 18/12/2014
Rapid review outcome Full Pharmacoeconomic Assessment Recommended
Full pharmacoeconomic assessment commissioned by HSE 18/03/2015
NCPE assessment completed 20/11/2015
NCPE assessment outcome Reimbursement Recommended for Genotype 1 and 4.